حول Summit Therapeutics Sub
Summit is committed to leadership in resolving serious, unmet medical needs in oncology for the betterment of overall HUMAN HEALTH. Stifel Fireside Chat Patients & Caregivers Summit Latest News Committed to Optimizing Human Health Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly
37 فرصة عمل في Summit Therapeutics Sub
Cmc Manager, Drug Substance
118500 - 139500
CMC Manager Drug SubstanceLocation: Onsite - Menlo Park CA Miami FL Princeton NJ or Oxford UKOverview of Role:The CMC Manager Drug Substance will play a crucial role in supporting the Director CMC Drug Substance. This position involves managing and overseeing the Chemistry Manufacturi المزيد...
Senior Manager, Clinical Data Scientist
170000 - 190000
Location: On-Site 4 days per week at our Menlo Park CA officeOverview of Role: Summit is looking for a highly motivated Sr. Manager/ Principal Clinical Data Scientist to join our growing team. This role will play a critical part in advancing our technology and data-driven clinical dat المزيد...
Associate Director, Facility Management
168000 - 180000
ASSOCIATE DIRECTOR FACILITY MANAGMENT Location: Palo Alto CA About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated wi المزيد...
Assistant Controller
215000 - 235000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Senior Manager, It Security, Compliance & Infrastructure
153000 - 180000
Sr. Manager IT Security Compliance & InfrastructureLocation: Onsite in Palo Alto CA or Princeton NJ About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with المزيد...
Director, Medical Affairs
230000 - 288000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
Director, Clinical Scientist
200000 - 240000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Manager, Regulatory Cmc
135000 - 150000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Medical Director
230000 - 270000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Finance Manager (r&d)
134500 - 155000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab display المزيد...
Senior Financial Analyst (r&d Finance/accounting)
134000 - 155000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab display المزيد...
Corporate Paralegal
120000 - 135000
Overview of Role: We are seeking a proactive and detail-oriented Corporate Paralegal to join our quickly growing team at a publicly traded company. This role provides support across corporate governance securities compliance contracting and other general corporate addition they will المزيد...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
**THIS POSITION WILL BE ON-SITE AT OUR MIAMI FL OFFICE or MENLO PARK CA OFFICE**About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi المزيد...
Senior Director, Cmc Strategy Development & Delivery
221000 - 277000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Director, Quality Assurance
186000 - 233000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
Accounting Manager, R&d
118500 - 139500
Job Title: Accounting Manager R&DDepartment: FinanceLocation: Menlo Park CA ONSITEJob Type: Full-Time ACCOUNTING MANAGER R&D About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy المزيد...
Director, Accounting
184000 - 230000
LOCATION: Position will be on-site in Menlo Park CA or Princeton NJAbout Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associa المزيد...
Associate Director, Clinical Operations
168500 - 198500
Location: On-Site 4 days per week at ourMenlo Park CA Princeton NJ or Miami FL officeAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis المزيد...
Manager, Clinical Study Start Up (contract)
50 - 60
*THIS IS A TEMPORARY POSITION*About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single المزيد...
